This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
home:starting:physician:reluctant [04.15.2019] – [Specific research] sallieq | home:starting:physician:reluctant [06.01.2019] – [Specific research] sallieq | ||
---|---|---|---|
Line 176: | Line 176: | ||
[[home: | [[home: | ||
- | OLM refs to print; | + | OLMesartan references |
- | including | + | include |
Line 185: | Line 185: | ||
{{ : | {{ : | ||
- | The ROADMAP study will answer the question whether an ARB can prevent or delay the onset of microalbuminuria and whether this translates into protection against cardiovascular events and renal disease. (({{pubmed> | + | The ROADMAP study will answer the question whether an ARB can prevent or delay the onset of microalbuminuria and whether this translates into protection against cardiovascular events and renal disease. (({{pubmed> |
short extract for each research study follows: | short extract for each research study follows: | ||
- | Benefits of RAS blockade with olmesartan treatment are sustained after study discontinued. (({{pubmed> | + | Benefits of RAS blockade with olmesartan treatment are sustained after study discontinued. (({{pubmed> |
- | Olmesartan significantly reduced myocardial infarct size and improved LV contractility at a dose (3 mg/kg) with systemic vasodilating effects but not at a lower dose (0.3 mg/kg) without hemodynamic effects.(in rat)(({{pubmed> | + | Olmesartan significantly reduced myocardial infarct size and improved LV contractility at a dose (3 mg/kg) with systemic vasodilating effects but not at a lower dose (0.3 mg/kg) without hemodynamic effects.[in rat](({{pubmed> |
- | Inhibition of renin-angiotensin system attenuates periadventitial inflammation and reduces atherosclerotic lesion formation. (({{pubmed> | + | Inhibition of renin-angiotensin system attenuates periadventitial inflammation and reduces atherosclerotic lesion formation. (({{pubmed> |
- | Olmesartan and Bay11-7082 inhibit the MCF-7 cells growth indicating RAS and NF-kappaB pathway blockade lead to cytotoxicity & apoptosis induction against tumour cells in breast cancer (({{pubmed> | + | Olmesartan and Bay11-7082 inhibit the MCF-7 cells growth indicating RAS and NF-kappaB pathway blockade lead to cytotoxicity & apoptosis induction against tumour cells in breast cancer (({{pubmed> |
10) | 10) | ||
- | Alzheimer' | + | Alzheimer' |
- | prevent migraines (({{pubmed> | + | prevent migraines (({{pubmed> |
- | inhibit liver fibrosis and aid liver healing (({{pubmed> | + | inhibit liver fibrosis and aid liver healing (({{pubmed> |
- | 6 mg/kg olmesartan reduces the inflammatory process and bone loss in rats (({{pubmed> | + | 6 mg/kg olmesartan reduces the inflammatory process and bone loss [in rats] (({{pubmed> |
+ | Olmesartan at a dose of 10 mg/kg prevented the mucosal damage and inflammation associated with 5-FU-induced OM, increasing granulation and tissue repair. [in hamsters] (({{pubmed> | ||
- | protect the mitochondria from age-associated damage from oxidation (({{pubmed> | ||
+ | protect the mitochondria from age-associated damage from oxidation (({{pubmed> | ||
- | reduce liver fibrosis (({{pubmed> | ||
+ | reduce liver fibrosis (({{pubmed> | ||
- | treatment of anxiety and stress-related disorders (({{pubmed> | ||
+ | treatment of anxiety and stress-related disorders (({{pubmed> | ||
- | inflammation in myocarditis (({{pubmed> | ||
+ | inflammation in myocarditis (({{pubmed> | ||
- | C-reactive protein, one of the acute phase proteins that increase during systemic inflammation (({{pubmed> | ||
+ | C-reactive protein, one of the acute phase proteins that increase during systemic inflammation (({{pubmed> | ||
- | cytokine damage (({{pubmed> | ||
- | in circadian rhythms between HR and MAP in CKD: Synchronization between the two rhythms was progressively lost as renal function deteriorated, | + | cytokine damage |
- | renal protective effects of olmesartan may be better than those of other ARBs (({{pubmed> | + | in circadian rhythms between HR and MAP in CKD: Synchronization between the two rhythms was progressively lost as renal function deteriorated, |
- | olmesartan may uniquely increase urinary ACE2 level, which could offer additional renoprotective effects | + | renal protective effects of olmesartan may be better than those of other ARBs (({{pubmed> |
+ | olmesartan may uniquely increase urinary ACE2 level, which could offer additional renoprotective effects (({{pubmed> | ||
- | * treatment with olmesartan inhibited bone loss (({{pubmed> | ||
+ | * treatment with olmesartan inhibited bone loss (({{pubmed> | ||
- | * olmesartan protects endothelial cells against oxidative stress-mediated cellular injury (({{pubmed> | ||
+ | * olmesartan protects endothelial cells against oxidative stress-mediated cellular injury (({{pubmed> | ||
- | * decreases viability of malignant cell lines(({{pubmed> | ||
+ | * decreases viability of malignant cell lines(({{pubmed> | ||
- | * carotid IMT and BP decreased similarly with olmesartan and atenolol; but only olmesartan reduced the volume of larger atherosclerotic plaques (({{pubmed> | ||
+ | * carotid IMT and BP decreased similarly with olmesartan and atenolol; but only olmesartan reduced the volume of larger atherosclerotic plaques (({{pubmed> | ||
- | * improvement of Plasma Biomarkers after switching stroke patients from other Angiotensin II Type I Receptor Blockers to Olmesartan (({{pubmed> | ||
+ | * improvement of Plasma Biomarkers after switching stroke patients from other Angiotensin II Type I Receptor Blockers to Olmesartan (({{pubmed> | ||
- | * improvement of glycemic control & insulin resistance was only observed in olmesartan group (({{pubmed> | ||
+ | * improvement of glycemic control & insulin resistance was only observed in olmesartan group (({{pubmed> | ||
- | * OLM substantially delayed the development of left ventricular remodeling in type 2 diabetes (({{pubmed> | ||
+ | * OLM substantially delayed the development of left ventricular remodeling in type 2 diabetes (({{pubmed> | ||
- | * prevention of microalbuminuria in patients with type 2 diabetes and hypertension (({{pubmed> | ||
+ | * prevention of microalbuminuria in patients with type 2 diabetes and hypertension (({{pubmed> | ||
- | Recent studies showed treatment with olmesartan inhibited bone loss (({{pubmed> | ||
+ | Recent studies showed treatment with olmesartan inhibited bone loss (({{pubmed> | ||
- | olmesartan protects endothelial cells against oxidative stress-mediated cellular injury (({{pubmed> | ||
+ | olmesartan protects endothelial cells against oxidative stress-mediated cellular injury (({{pubmed> | ||
- | decreases viability of malignant cell lines (({{pubmed> | + | |
+ | decreases viability of malignant cell lines (({{pubmed> | ||
carotid IMT and BP decreased similarly with olmesartan and atenolol; but only olmesartan reduced | carotid IMT and BP decreased similarly with olmesartan and atenolol; but only olmesartan reduced | ||
- | the volume of larger atherosclerotic plaques (({{pubmed> | + | the volume of larger atherosclerotic plaques (({{pubmed> |
+ | |||
+ | Observations suggest a positive role in a potentially lower rate of coronary atheroma progression through the administration of olmesartan, an angiotension-II receptor blocking agent, for patients with stable angina pectoris. | ||
+ | This study showed that olmesartan reduces angiotensin II and aldosterone levels more effectively than azilsartan. | ||
- | improvement of Plasma Biomarkers after switching stroke patients from other Angiotensin II Type I Receptor Blockers to Olmesartan (({{pubmed> | + | improvement of Plasma Biomarkers after switching stroke patients from other Angiotensin II Type I Receptor Blockers to Olmesartan (({{pubmed> |
- | improvement of glycemic control & insulin resistance was only observed in olmesartan group (({{pubmed> | + | improvement of glycemic control & insulin resistance was only observed in olmesartan group (({{pubmed> |
- | OLM substantially delayed the development of left ventricular remodeling in type 2 diabetes (({{pubmed> | + | OLM substantially delayed the development of left ventricular remodeling in type 2 diabetes (({{pubmed> |
- | Long term treatment Data suggest 40 & 80 mg olmesartan are able to significantly remodel & destiffen the arterial wall material during long-term treatment, partly independently of blood pressure, compared with 20 mg. hyper.ahajournals.org/ | + | Long term treatment Data suggest 40 & 80 mg olmesartan are able to significantly remodel & destiffen the arterial wall material during long-term treatment, partly independently of blood pressure, compared with 20 mg. hyper.ahajournals.org/ |
Line 294: | Line 299: | ||
{{section>: | {{section>: | ||
- | {{tag> | + | {{tag> |
===== Notes and comments ===== | ===== Notes and comments ===== |